These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

585 related items for PubMed ID: 30707764

  • 1. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
    Godfrey JK, Nabhan C, Karrison T, Kline JP, Cohen KS, Bishop MR, Stadler WM, Karmali R, Venugopal P, Rapoport AP, Smith SM.
    Cancer; 2019 Jun 01; 125(11):1830-1836. PubMed ID: 30707764
    [Abstract] [Full Text] [Related]

  • 2. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
    Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH.
    Lancet Haematol; 2018 Dec 01; 5(12):e609-e617. PubMed ID: 30501868
    [Abstract] [Full Text] [Related]

  • 3. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
    Rutherford SC, Abramson JS, Bartlett NL, Barta SK, Khan N, Joyce R, Maddocks K, Ali-Shaw T, Senese S, Yuan Y, Westin J, Leonard JP.
    Lancet Haematol; 2021 Nov 01; 8(11):e818-e827. PubMed ID: 34634256
    [Abstract] [Full Text] [Related]

  • 4. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
    Zhang XY, Liang JH, Wang L, Zhu HY, Wu W, Cao L, Fan L, Li JY, Xu W.
    J Cancer Res Clin Oncol; 2019 Jan 01; 145(1):117-127. PubMed ID: 30327941
    [Abstract] [Full Text] [Related]

  • 5. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
    Chiappella A, Tucci A, Castellino A, Pavone V, Baldi I, Carella AM, Orsucci L, Zanni M, Salvi F, Liberati AM, Gaidano G, Bottelli C, Rossini B, Perticone S, De Masi P, Ladetto M, Ciccone G, Palumbo A, Rossi G, Vitolo U, Fondazione Italiana Linfomi.
    Haematologica; 2013 Nov 01; 98(11):1732-8. PubMed ID: 23812930
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements.
    McPhail ED, Maurer MJ, Macon WR, Feldman AL, Kurtin PJ, Ketterling RP, Vaidya R, Cerhan JR, Ansell SM, Porrata LF, Nowakowski GS, Witzig TE, Habermann TM.
    Haematologica; 2018 Nov 01; 103(11):1899-1907. PubMed ID: 29903764
    [Abstract] [Full Text] [Related]

  • 8. Patterns of Failure in Patients With Double Hit or Double Expressor Lymphomas: Implications for Radiation Therapy.
    Tumati V, Trivedi L, Li HC, Patel P, Scaglioni PP, Vusirikala M, Sadeghi N, Rizvi S, Chen W, Wachsmann J, Collins R, Desai NB.
    Int J Radiat Oncol Biol Phys; 2018 Apr 01; 100(5):1126-1132. PubMed ID: 29722657
    [Abstract] [Full Text] [Related]

  • 9. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.
    Kühnl A, Cunningham D, Counsell N, Hawkes EA, Qian W, Smith P, Chadwick N, Lawrie A, Mouncey P, Jack A, Pocock C, Ardeshna KM, Radford J, McMillan A, Davies J, Turner D, Kruger A, Johnson PW, Gambell J, Rosenwald A, Ott G, Horn H, Ziepert M, Pfreundschuh M, Linch D.
    Ann Oncol; 2017 Jul 01; 28(7):1540-1546. PubMed ID: 28398499
    [Abstract] [Full Text] [Related]

  • 10. Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma.
    Chen AI, Leonard JT, Okada CY, Gay ND, Chansky K, Fan G, Dunlap JB, Raess PW, Braziel RM, Stentz A, Maziarz RT.
    Leuk Lymphoma; 2018 Aug 01; 59(8):1884-1889. PubMed ID: 29199519
    [Abstract] [Full Text] [Related]

  • 11. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U.
    Lancet Oncol; 2017 Aug 01; 18(8):1076-1088. PubMed ID: 28668386
    [Abstract] [Full Text] [Related]

  • 12. Perspectives on chemotherapy for the management of double-hit lymphoma.
    Al-Juhaishi T, Mckay J, Sindel A, Yazbeck V.
    Expert Opin Pharmacother; 2020 Apr 01; 21(6):653-661. PubMed ID: 32066288
    [Abstract] [Full Text] [Related]

  • 13. A Retrospective Study of Double-hit Lymphomas in Elderly Patients (Aged > 70 Years): Overall Outcomes.
    Hancock C, Knouse P, Almanaseer I, Bitran J.
    Clin Lymphoma Myeloma Leuk; 2018 Apr 01; 18(4):280-285. PubMed ID: 29500147
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
    Johnston PB, LaPlant B, McPhail E, Habermann TM, Inwards DJ, Micallef IN, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE.
    Lancet Haematol; 2016 Jul 01; 3(7):e309-16. PubMed ID: 27374464
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.
    Xia Y, Zhang X.
    Acta Haematol; 2020 Jul 01; 143(6):520-528. PubMed ID: 32074595
    [Abstract] [Full Text] [Related]

  • 18. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.
    Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, Özcan M, Hong X, Zhu J, Jin J, Belada D, Bergua JM, Piazza F, Mócikova H, Molinari AL, Yoon DH, Cavallo F, Tani M, Yamamoto K, Izutsu K, Kato K, Czuczman M, Hersey S, Kilcoyne A, Russo J, Hudak K, Zhang J, Wade S, Witzig TE, Vitolo U.
    J Clin Oncol; 2021 Apr 20; 39(12):1317-1328. PubMed ID: 33621109
    [Abstract] [Full Text] [Related]

  • 19. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
    Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberley MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP.
    Br J Haematol; 2017 Dec 20; 179(5):739-747. PubMed ID: 29082519
    [Abstract] [Full Text] [Related]

  • 20. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
    Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G, Spina M, Pavone V, Ladetto M, Liberati AM, Molinari AL, Zinzani P, Salvi F, Fattori PP, Zaccaria A, Dreyling M, Botto B, Castellino A, Congiu A, Gaudiano M, Zanni M, Ciccone G, Gaidano G, Rossi G, Fondazione Italiana Linfomi.
    Lancet Oncol; 2014 Jun 20; 15(7):730-7. PubMed ID: 24831981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.